Short answer
Keros Therapeutics, Inc. (KROS) filed an 8-K current report with the SEC on July 30, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). $20 million development milestone payment from Takeda following first-patient dosing in Phase 3 ELRiSE MDS trial.
Keros Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- $20 million development milestone payment from Takeda following first-patient dosing in Phase 3 ELRiSE MDS trial
- Elritercept advancing to Phase 3 against epoetin alfa for anemia in very low-, low-, or intermediate-risk MDS
- Milestone validates continued partner investment while providing non-dilutive cash to Keros
- Disclosure furnished under Regulation FD and not incorporated into other SEC filings by reference
Item EX-99.1 · Exhibit EX-99.1
- $20 million development milestone triggered by first-patient dosing in Takeda’s Phase 3 ELRiSE MDS trial
- Phase 3 trial compares elritercept against epoetin alfa for anemia in very low-, low-, or intermediate-risk MDS
- Keros eligible for development, commercial, and sales milestones potentially exceeding $1.1 billion, plus tiered royalties
- Company expects to distribute 25% of net milestone proceeds to stockholders
- Milestone validates continued program advancement but remains subject to Phase 3 execution and regulatory risks
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Keros Therapeutics, Inc. 8-K filings
Get the next KROS 8-K as it lands
Follow KROS for push alerts, or ask the research agent what this filing means.